Form 8-K - Current report:
SEC Accession No. 0001558370-25-000726
Filing Date
2025-02-10
Accepted
2025-02-10 07:30:14
Documents
14
Period of Report
2025-02-05
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20250205x8k.htm   iXBRL 8-K 33378
  Complete submission text file 0001558370-25-000726.txt   161177

Data Files

Seq Description Document Type Size
2 EX-101.SCH sngx-20250205.xsd EX-101.SCH 4025
3 EX-101.DEF sngx-20250205_def.xml EX-101.DEF 3490
4 EX-101.LAB sngx-20250205_lab.xml EX-101.LAB 17253
5 EX-101.PRE sngx-20250205_pre.xml EX-101.PRE 10057
17 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20250205x8k_htm.xml XML 4794
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 25603662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)